Market Overview

Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

Related AEZS
Aeterna Zentaris Reports Data, Safety Monitoring Board Scheduled to Close Second Interim Analysis of ZoptEC Phase 3 Trial in Early October
Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that on October 19, 2012, NASDAQ notified the Company that it has regained compliance with Rule 5450(a)(1), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Global Market.

Commenting on the announcement, Juergen Engel, Ph.D., President and Chief Executive Officer, stated: "We are pleased that we have been able to regain compliance with NASDAQ's minimum bid price rule, which is important in maintaining liquidity in the trading of our common shares. We will continue to pursue our objective of maximizing shareholder value with a goal of becoming a specialty oncology and endocrinology company developing drugs for indications with various unmet medical needs."

Posted-In: News


Related Articles (AEZS)

Get Benzinga's Newsletters